Argenx
ARGX
511,23 €
Share price
6.36%
Change (1 day)
44.45%
Change (1 year)
Categories
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.
P/S ratio for Argenx (ARGX)
P/S ratio as of April 2025 (TTM): 16.2
According to Argenx 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 6.47. At the end of 2024 the company had a P/S ratio of 17.1.
P/S ratio history for Argenx from 2022 to 2021
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2024 | 17.1 | -7.08% |
| 2023 | 18.4 | -63.94% |
| 2022 | 51.0 | -17.81% |
| 2021 | 62.1 | |
| 2019 | 78.5 | -34.79% |
| 2018 | 120 | 201.66% |
| 2017 | 39.9 | |
| 2014 | 25.2 |